LncRNA-Ang362 Promotes Pulmonary Arterial Hypertension by Regulating miR-221 and miR-222.
Pulmonary arterial hypertension is a life-threatening cardiopulmonary disorder. LncRNA-Ang362 (lnc-Ang362) regulates miR-221 and miR-222 in vascular smooth muscle cell proliferation, which can lead to pulmonary arterial hypertension. The present study was design to investigate the function and underlying mechanisms of lnc-Ang362 in pulmonary arterial hypertension (PAH). The expression of lnc-Ang362, miR-221 and miR-222 in 15 PAH patients and 10 healthy controls were measured by qRT-PCR. Lnc-Ang362 overexpression vector and siRNA were transfected into human pulmonary arterial smooth muscle cells (HPASMCs), and cell proliferation, migration, apoptosis rate were assessed. The protein expression of p-p65 and p-IκBα were measured by western blot. MiR-221 or miR-222 inhibitor were co-transfected with lnc-Ang362 overexpression vector into HPASMCs. Data from the present study showed significantly increased lnc-Ang362, miR-221, and miR-222 expression in the lung tissues of patients with pulmonary arterial hypertension and in hypoxic human pulmonary arterial smooth muscle cells. Whereas overexpression of lnc-Ang362 promoted proliferation and migration of human pulmonary arterial smooth muscle cells, inhibition of lnc-Ang362 had the opposite effect. Additionally, apoptosis of human pulmonary arterial smooth muscle cells significantly decreased after lnc-Ang362 overexpression and increased after lnc-Ang362 inhibition. Meanwhile, lnc-Ang362 upregulated miR-221 and miR-222 expression and activated the NFκB signaling pathway in human pulmonary arterial smooth muscle cells. Moreover, miR-221 and the miR-222 inhibitor both attenuated the proliferation and migration effects of lnc-Ang362 and elevated apoptosis in these cells. Lnc-Ang362 played an important role in regulating the biological function of human pulmonary arterial smooth muscle cells by promoting miR-221 and miR-222. Lnc-Ang362 thus may be a novel therapeutic lncRNA candidate for treating pulmonary arterial hypertension.